$PTPI
Petros Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000141057823002502 Filed on November 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $5.822M $1.675M
YoY Change 629.53% -214.88%
Cost Of Revenue $1.631M $408.5K
YoY Change 85.09% 42.56%
Gross Profit $4.191M $1.266M
YoY Change -5135.65% -172.59%
Gross Profit Margin 71.98% 75.61%
Selling, General & Admin $9.261M $2.002M
YoY Change 216.76% -7.79%
% of Gross Profit 220.98% 158.11%
Research & Development $2.409M $389.1K
YoY Change 1255.25% -47.13%
% of Gross Profit 57.48% 30.73%
Depreciation & Amortization $802.6K $826.8K
YoY Change -12.41% -47.03%
% of Gross Profit 19.15% 65.3%
Operating Expenses $17.81M $6.073M
YoY Change 343.23% -49.09%
Operating Profit -$13.62M -$4.807M
YoY Change 232.04% -64.84%
Interest Expense $2.569M -$392.9K
YoY Change -2064.95% 166.03%
% of Operating Profit
Other Income/Expense, Net $2.885M $650.0K
YoY Change
Pretax Income -$8.163M -$4.550M
YoY Change 92.9% -67.08%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.81M -$4.550M
YoY Change 227.25% -67.1%
Net Earnings / Revenue -237.26% -271.67%
Basic Earnings Per Share -$2.31
Diluted Earnings Per Share -$6.35 -$2.31
COMMON SHARES
Basic Shares Outstanding 2.201M 2.114M
Diluted Shares Outstanding 2.120M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.34M $17.97M
YoY Change 41.49% 60.71%
Cash & Equivalents $13.30M $18.00M
Short-Term Investments
Other Short-Term Assets $3.217M $57.56K
YoY Change 2227.26% -59.34%
Inventory $1.610M $2.501M
Prepaid Expenses
Receivables $2.226M $2.975M
Other Receivables $0.00 $0.00
Total Short-Term Assets $20.39M $24.43M
YoY Change 39.01% 30.16%
LONG-TERM ASSETS
Property, Plant & Equipment $255.2K $31.51K
YoY Change 551.45% -24.49%
Goodwill
YoY Change
Intangibles $8.972M $9.772M
YoY Change -26.73% -25.74%
Long-Term Investments
YoY Change
Other Assets $4.178M $4.417M
YoY Change 1065.63% 1035.21%
Total Long-Term Assets $13.41M $14.48M
YoY Change -24.49% -23.48%
TOTAL ASSETS
Total Short-Term Assets $20.39M $24.43M
Total Long-Term Assets $13.41M $14.48M
Total Assets $33.80M $38.91M
YoY Change 4.24% 3.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.713M $1.355M
YoY Change -5.16% -34.99%
Accrued Expenses $7.457M $3.869M
YoY Change 105.16% -13.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.157M $1.139M
YoY Change 6.14% 25.76%
Total Short-Term Liabilities $10.77M $8.082M
YoY Change 52.39% 1.73%
LONG-TERM LIABILITIES
Long-Term Debt $6.857M $7.249M
YoY Change -18.25% -17.22%
Other Long-Term Liabilities $3.688M $151.4K
YoY Change 1303.87% -49.56%
Total Long-Term Liabilities $10.55M $151.4K
YoY Change 3914.43% -49.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.77M $8.082M
Total Long-Term Liabilities $10.55M $151.4K
Total Liabilities $21.32M $31.86M
YoY Change 35.61% 87.38%
SHAREHOLDERS EQUITY
Retained Earnings -$98.90M -$99.20M
YoY Change 9.04% 14.68%
Common Stock $298.00 $211.00
YoY Change 43.27% -89.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.48M $6.933M
YoY Change
Total Liabilities & Shareholders Equity $33.80M $38.91M
YoY Change 4.24% 3.23%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$13.81M -$4.550M
YoY Change 227.25% -67.1%
Depreciation, Depletion And Amortization $802.6K $826.8K
YoY Change -12.41% -47.03%
Cash From Operating Activities -$2.260M -$4.047M
YoY Change 43.91% 131.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.373M 14.63M
YoY Change 1182.4% -4141.97%
NET CHANGE
Cash From Operating Activities -2.260M -4.047M
Cash From Investing Activities
Cash From Financing Activities -2.373M 14.63M
Net Change In Cash -4.633M 10.58M
YoY Change 163.93% -600.78%
FREE CASH FLOW
Cash From Operating Activities -$2.260M -$4.047M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssets
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001815903
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
13846
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
13846
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2119620
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2079387
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2119620
us-gaap Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
true
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssets
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39752
dei Entity Registrant Name
EntityRegistrantName
Petros Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1410058
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
973
dei Local Phone Number
LocalPhoneNumber
242-0005
dei Security12b Title
Security12bTitle
Common stock
dei Trading Symbol
TradingSymbol
PTPI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2201069
CY2023Q3 us-gaap Cash
Cash
17969949
CY2022Q4 us-gaap Cash
Cash
9426264
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2975018
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2110246
CY2023Q3 us-gaap Inventory Net
InventoryNet
2501093
CY2022Q4 us-gaap Inventory Net
InventoryNet
1815113
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
987120
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1316282
CY2023Q3 us-gaap Assets Current
AssetsCurrent
24433180
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14667905
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31513
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39177
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9771764
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12244484
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
4416862
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5111176
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
260849
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
358472
CY2023Q3 us-gaap Assets
Assets
38914168
CY2022Q4 us-gaap Assets
Assets
32421214
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1139458
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1089683
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1355060
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1806399
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3869027
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3634662
CY2023Q3 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
1368546
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
349972
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
537232
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8082063
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7067976
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
7248635
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8388093
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
6570000
CY2023Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
9805000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
151395
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
262678
CY2023Q3 us-gaap Liabilities
Liabilities
31857093
CY2022Q4 us-gaap Liabilities
Liabilities
15718747
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
1000
CY2022Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
1000
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
15000000
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
124532
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2079387
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
211
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
208
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106140063
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
107428652
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99207731
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90726393
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6932543
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16702467
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38914168
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32421214
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
6186638
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
5193953
CY2023Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
1674657
CY2022Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
-1457732
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1473073
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1408086
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
408475
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
286525
us-gaap Gross Profit
GrossProfit
4713565
us-gaap Gross Profit
GrossProfit
3785867
CY2023Q3 us-gaap Gross Profit
GrossProfit
1266182
CY2022Q3 us-gaap Gross Profit
GrossProfit
-1744257
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6382166
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9285317
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2001935
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2170975
ptpi Warrants Issuance Costs
WarrantsIssuanceCosts
2855000
CY2023Q3 ptpi Warrants Issuance Costs
WarrantsIssuanceCosts
2855000
ptpi Gain Loss On Settlement With Vivus
GainLossOnSettlementWithVivus
3389941
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1574760
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1562518
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
389093
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
735916
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2480385
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4682610
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
826795
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1560870
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7460000
CY2022Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7460000
us-gaap Operating Expenses
OperatingExpenses
13292311
us-gaap Operating Expenses
OperatingExpenses
19600504
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6072823
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11927761
us-gaap Operating Income Loss
OperatingIncomeLoss
-8578746
us-gaap Operating Income Loss
OperatingIncomeLoss
-15814637
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4806641
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13672018
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-430000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
460000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-430000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11739000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11739000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
287722
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
168481
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
410317
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
451075
CY2023Q3 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
131351
CY2022Q3 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
147677
ptpi Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
-11088997
CY2023Q3 ptpi Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
-11088997
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8481338
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15805712
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4549508
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13819695
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10501
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10501
us-gaap Net Income Loss
NetIncomeLoss
-8481338
us-gaap Net Income Loss
NetIncomeLoss
-15816213
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4549508
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13830196
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
339232
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
339232
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8820570
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15816213
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4888740
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13830196
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.65
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.69
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.69
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2108747
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2108747
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2068472
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2068472
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2119620
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2119620
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2068472
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2068472
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12944289
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30840
CY2023Q3 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
1153846
CY2023Q3 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
249701
CY2023Q3 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
89531
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4549508
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6932543
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16702467
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204492
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
1153846
us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
249701
CY2023Q3 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
89531
us-gaap Net Income Loss
NetIncomeLoss
-8481338
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6932543
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
34217041
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
308138
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13830196
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20694982
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35544964
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
966231
us-gaap Net Income Loss
NetIncomeLoss
-15816213
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20694982
us-gaap Profit Loss
ProfitLoss
-8481338
us-gaap Profit Loss
ProfitLoss
-15816213
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2480385
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4682610
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7460000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
32516
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-103650
ptpi Inventory And Sample Inventory Reserve
InventoryAndSampleInventoryReserve
41195
ptpi Inventory And Sample Inventory Reserve
InventoryAndSampleInventoryReserve
-14688
us-gaap Operating Lease Expense
OperatingLeaseExpense
97622
us-gaap Operating Lease Expense
OperatingLeaseExpense
86477
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-430000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
460000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11739000
ptpi Loss On Issuance Of Series Preferred Stock
LossOnIssuanceOfSeriesPreferredStock
11088997
ptpi Noncash Warrant Expense
NoncashWarrantExpense
1595000
ptpi Gain Loss On Settlement With Vivus
GainLossOnSettlementWithVivus
3389941
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
204492
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
966231
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
897289
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1174106
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
63191
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1619694
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-359492
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1478267
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-451338
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2473450
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
234364
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-954607
ptpi Increase Decrease Of Deferred Revenue
IncreaseDecreaseOfDeferredRevenue
-281372
ptpi Increase Decrease Of Deferred Revenue
IncreaseDecreaseOfDeferredRevenue
56274
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
94113
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
154370
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-111283
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-104865
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5366635
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11226985
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-1089683
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-1438925
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15000003
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13910320
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1438925
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8543685
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12665910
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9426264
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23847572
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17969949
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11181662
us-gaap Interest Paid Net
InterestPaidNet
410317
us-gaap Interest Paid Net
InterestPaidNet
451075
ptpi Noncash Decrease In Accrued Expenses Related To Vivus Settlement
NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement
-6520283
ptpi Noncash Decrease In Accrued Inventory Purchases Related To Vivus Settlement
NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement
-14203905
ptpi Noncash Increase In Promissory Note Related To Vivus Settlement
NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement
10201758
ptpi Non Cash Acquisition Active Pharmaceutical Ingredient Of Purchase Agreement
NonCashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement
663984
ptpi Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement
NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement
694314
ptpi Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement
NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement
6232489
ptpi Noncash Decrease In Other Current Assets Api Purchase Commitment
NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment
-30330
ptpi Noncash Issuance Of Common Stock To Non Employee
NoncashIssuanceOfCommonStockToNonEmployee
3
ptpi Noncash Issuance Of Common Stock To Non Employee
NoncashIssuanceOfCommonStockToNonEmployee
3
ptpi Noncash Initial Fair Value Of Warrant Liability Pursuant To Private Placement
NoncashInitialFairValueOfWarrantLiabilityPursuantToPrivatePlacement
21544000
ptpi Noncash Initial Fair Value Of Derivative Liability Pursuant To Private Placement
NoncashInitialFairValueOfDerivativeLiabilityPursuantToPrivatePlacement
6140000
ptpi Accrued Series Convertible Preferred Payments Payable
AccruedSeriesConvertiblePreferredPaymentsPayable
1368546
ptpi Accretion Of Series Convertible Preferred Stock To Redemption Value
AccretionOfSeriesConvertiblePreferredStockToRedemptionValue
1250000
ptpi Accrual Of Series Convertible Preferred Stock Dividends
AccrualOfSeriesConvertiblePreferredStockDividends
339232
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18000000.0
CY2023Q3 ptpi Working Capital
WorkingCapital
16400000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99200000
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, exceed insured limits.</p>
CY2023Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2900000
CY2022Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2300000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
3800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1300000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7600000
CY2023Q3 us-gaap Accrued Exchange Fee Rebate Current And Noncurrent
AccruedExchangeFeeRebateCurrentAndNoncurrent
49499
CY2022Q4 us-gaap Accrued Exchange Fee Rebate Current And Noncurrent
AccruedExchangeFeeRebateCurrentAndNoncurrent
279018
CY2021Q4 us-gaap Accrued Exchange Fee Rebate Current And Noncurrent
AccruedExchangeFeeRebateCurrentAndNoncurrent
379242
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
281372
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
70343
CY2022Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7500000
CY2023Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
3713405
CY2022Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
2757839
CY2021Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
3363827
CY2023Q3 ptpi Accounts Receivable Distribution Service Fees
AccountsReceivableDistributionServiceFees
358661
CY2022Q4 ptpi Accounts Receivable Distribution Service Fees
AccountsReceivableDistributionServiceFees
339094
CY2021Q4 ptpi Accounts Receivable Distribution Service Fees
AccountsReceivableDistributionServiceFees
371310
CY2023Q3 ptpi Accounts Receivable Chargebacks Accruals
AccountsReceivableChargebacksAccruals
7375
CY2022Q4 ptpi Accounts Receivable Chargebacks Accruals
AccountsReceivableChargebacksAccruals
1960
CY2023Q3 ptpi Accounts Receivable Cash Discount Allowances
AccountsReceivableCashDiscountAllowances
132967
CY2022Q4 ptpi Accounts Receivable Cash Discount Allowances
AccountsReceivableCashDiscountAllowances
99671
CY2021Q4 ptpi Accounts Receivable Cash Discount Allowances
AccountsReceivableCashDiscountAllowances
159446
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
239384
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
206868
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
377685
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
2975018
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2110246
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2455386
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2391190
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1574683
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
109903
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
240430
CY2023Q3 us-gaap Inventory Net
InventoryNet
2501093
CY2022Q4 us-gaap Inventory Net
InventoryNet
1815113
CY2023Q3 ptpi Inventory Finished Goods Valuation Reserves
InventoryFinishedGoodsValuationReserves
405495
CY2022Q4 ptpi Inventory Finished Goods Valuation Reserves
InventoryFinishedGoodsValuationReserves
364300
CY2023Q3 ptpi Inventory Raw Materials Valuation Reserves
InventoryRawMaterialsValuationReserves
2872977
CY2022Q4 ptpi Inventory Raw Materials Valuation Reserves
InventoryRawMaterialsValuationReserves
2872977
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
169588
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
109414
CY2022Q4 ptpi Prepaid Coupon Fee Current
PrepaidCouponFeeCurrent
71500
CY2023Q3 ptpi Prepaid Purchase Commitment Asset Current
PrepaidPurchaseCommitmentAssetCurrent
694314
CY2022Q4 ptpi Prepaid Purchase Commitment Asset Current
PrepaidPurchaseCommitmentAssetCurrent
663984
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
65655
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
333158
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
57563
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
138226
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
987120
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1316282
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
25293149
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5588665
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7460000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12244484
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2472720
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9771764
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
800027
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2800623
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1754328
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1442186
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1212871
CY2023Q3 ptpi Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1761729
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9771764
CY2023Q3 ptpi Accrued Product Returns
AccruedProductReturns
2853413
CY2022Q4 ptpi Accrued Product Returns
AccruedProductReturns
2311647
CY2023Q3 ptpi Accrued Contract Rebates
AccruedContractRebates
49499
CY2022Q4 ptpi Accrued Contract Rebates
AccruedContractRebates
279018
CY2023Q3 ptpi Due To Third Party Logistic Provider
DueToThirdPartyLogisticProvider
103161
CY2022Q4 ptpi Due To Third Party Logistic Provider
DueToThirdPartyLogisticProvider
155081
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
421523
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
427500
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
51620
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
441431
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
409796
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3869027
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3634662
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
152166
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
260000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
2500000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2760000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2760000
CY2022Q1 ptpi Security Deposit For Sub Lease Received
SecurityDepositForSubLeaseReceived
14000
ptpi Operating Lease Expense Per Month
OperatingLeaseExpensePerMonth
7000
us-gaap Operating Lease Cost
OperatingLeaseCost
134435
us-gaap Operating Lease Cost
OperatingLeaseCost
134435
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
44812
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
44812
us-gaap Sublease Income
SubleaseIncome
63000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
21000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
260849
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
358472
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148758
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
142340
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151395
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
262677
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
300153
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
405017
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.126
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.126
us-gaap Operating Lease Payments
OperatingLeasePayments
141677
us-gaap Operating Lease Payments
OperatingLeasePayments
140805
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
47226
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
46935
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
47697
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
155242
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
81107
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
82324
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
366370
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66217
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
300153
CY2023Q3 ptpi Operating Leases Future Minimum Payments Receivable Sub Lease Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear
21000
CY2023Q3 ptpi Operating Leases Future Minimum Payments Receivable Sub Lease In Next Twelve Months
OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInNextTwelveMonths
56000
CY2023Q3 ptpi Operating Leases Future Minimum Payments Receivable Sub Lease
OperatingLeasesFutureMinimumPaymentsReceivableSubLease
77000
CY2023Q3 ptpi Lessee Operating Lease Lease Not Yet Commenced Amount
LesseeOperatingLeaseLeaseNotYetCommencedAmount
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2507369
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
59067
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.02
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
156000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.99
ptpi Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
115400
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
33.40
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
210067
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M26D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
115400
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
54067
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M23D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.40
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1
CY2023Q2 ptpi Share Based Compensation Arrangement By Share Based Payment Award Number Of Directors To Whom Option Is Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted
4
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
39000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
0.99
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y
us-gaap Share Based Compensation
ShareBasedCompensation
204492
us-gaap Share Based Compensation
ShareBasedCompensation
966231
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8204117
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1004115
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1004115
ptpi Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
7200002
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8204117
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8820570
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15816213
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4888740
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13830196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2108747
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2108747
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2068472
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2068472
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2119620
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2119620
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2068472
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2068472
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.65
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.69
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15176274
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1105746
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15176274
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1105746
CY2023Q3 ptpi Collaborative Arrangement Accrued Inventory Purchases
CollaborativeArrangementAccruedInventoryPurchases
46288
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
6186638
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1473073
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6382166
ptpi Warrants Issuance Costs
WarrantsIssuanceCosts
2855000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1574760
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2480385
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-430000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11739000
us-gaap Interest Income Operating
InterestIncomeOperating
287722
us-gaap Interest Expense Debt
InterestExpenseDebt
410317
ptpi Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
-11088997
us-gaap Net Income Loss
NetIncomeLoss
-8481338
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
5193953
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1408086
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9285317
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
3389941
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1562518
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4682610
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7460000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
460000
us-gaap Interest Expense Debt
InterestExpenseDebt
451075
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10501
us-gaap Net Income Loss
NetIncomeLoss
-15816213
CY2023Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
1674657
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
408475
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2001935
CY2023Q3 ptpi Warrants Issuance Costs
WarrantsIssuanceCosts
2855000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
389093
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
826795
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-430000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11739000
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
168481
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
131351
CY2023Q3 ptpi Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
-11088997
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4549508
CY2022Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
-1457732
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
286525
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2170975
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
735916
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1560870
CY2022Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7460000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
147677
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10501
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13830196
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
6186638
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
5193953
CY2023Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
1674657
CY2022Q3 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
-1457732
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9771764
CY2023Q3 us-gaap Assets
Assets
38914168
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12244484
CY2022Q4 us-gaap Assets
Assets
32421214
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.25
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 ptpi Maximum Percentage Of Outstanding Shares Approved For Issuance In Accordance With Nasdaq Stock Market Rules
MaximumPercentageOfOutstandingSharesApprovedForIssuanceInAccordanceWithNasdaqStockMarketRules
0.1999
CY2023Q3 us-gaap Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee
EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee
0.29
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
21544000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-11739000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
9805000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
tmb-20230930_lab.xml Edgar Link unprocessable
tmb-20230930_pre.xml Edgar Link unprocessable
0001410578-23-002502-index-headers.html Edgar Link pending
0001410578-23-002502-index.html Edgar Link pending
0001410578-23-002502.txt Edgar Link pending
0001410578-23-002502-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230930.xsd Edgar Link pending
tmb-20230930x10q.htm Edgar Link pending
tmb-20230930xex31d1.htm Edgar Link pending
tmb-20230930xex31d2.htm Edgar Link pending
tmb-20230930xex32.htm Edgar Link pending
tmb-20230930_cal.xml Edgar Link unprocessable
tmb-20230930_def.xml Edgar Link unprocessable
tmb-20230930x10q_htm.xml Edgar Link completed